Navigation Links
Investigational agent targets gene signaling pathways to improve response for patients with CLL
Date:12/8/2012

uch patients are characterized by presence of chromosomal abnormalities (i.e., deletions of chromosome 17p or 11q) or short remissions (less than 3 years) after standard chemo-immunotherapy. To develop an alternative therapy regimen for this patient population, researchers explored the combination of ibrutinib and the anti-CD20 antibody rituximab in high-risk CLL.

In this Phase II study conducted at The University of Texas MD Anderson Cancer Center in Houston, ibrutinib was given in combination with rituximab to evaluate its potential to accelerate and improve CLL patient responses. Forty patients were treated with 420 mg of ibrutinib daily in combination with weekly rituximab for four weeks, followed by ibrutinib daily plus monthly rituximab until month six, followed by single-agent ibrutinib.

Positive responses to therapy were shown among the vast majority of treated patients. At four months of follow-up, the overall response rate was 85 percent and almost all (38 of 40) patients continued on therapy without disease progression. Of the 20 patients evaluable for early response, 17 achieved a partial remission. Patient health questionnaires also noted improvements in health and the quality of life of all treated patients.

Overall, the regimen was well-tolerated among participants, with little severe toxicity that was largely unrelated and short in duration. After treatment with ibrutinib-rituximab (iR) combination therapy, most cases of early lymphocytosis (increase in white blood cells that is a sign of infection), due to the ibrutinib-induced shift of CLL cells from lymph node tissues into the blood, peaked early and resolved; at four months of follow-up, only three treated patients had lymphocytosis that had not yet resolved. This shorter lymphocytosis duration, when compared to single-agent use of ibrutinib, is presumably related to the addition of rituximab.

"We know that high-risk CLL patients struggle with the effects of
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
2. Rilpivirine for HIV: Added benefit for single agent proven
3. Travel Services (MyTSOnline) in Valencia Teams Up With Vendors to Become the Number One Travel Agent in the Santa Clarita Valley
4. Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer
5. Scientists ID Cancer-Causing Agent in Smokeless Tobacco
6. Therapy combining exercise and neuroprotective agent shows promise for stroke victims
7. New substances 15,000 times more effective in destroying chemical warfare agents
8. Difficult to diagnose cases of infectious endocarditis solved with SPECT/CT imaging agent
9. Imaging agents predict breast cancer response to endocrine therapy
10. Pig stomach mucins are effective as anti-viral agents for consumer products
11. Method developed by VTT targets diagnosis of early Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... BOSTON (May 21, 2013) Prostaglandin analogues (PGAs), drugs ... of treatment for people with glaucoma, but their use ... with blurred vision, dryness, changes in eye color and ... that these drugs also cause upper and lower eyelid ... The findings are described in PLOS ONE . ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... to protecting the rights of victims injured by defective ... Journal of Bone & Joint Surgery on May 15, ... can be used to identify complications that occur in ... any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
(Date:5/21/2013)... Texas (PRWEB) May 21, 2013 HealthSmart ... Its expanding national presence has required the hiring of ... , HealthSmart is pleased to announce that Dawn Powell ... is serving as the Director of Account Management in ... Corporate offices in Irving, Texas. With extensive client management, ...
(Date:5/21/2013)... May 2013, Paris, France: One-year results from SOURCE XT ... implantation (TAVI) registries to-date reported today at EuroPCR ... with high rates of device success for all access ... XT Post-Approval Study followed up 2688 consecutively enrolled patients ... XT heart valve at 93 centres in 17 countries ...
(Date:5/21/2013)... AZ (PRWEB) May 21, 2013 ... and inventors who want to develop their ideas ... summer program. , The university is recruiting ... revolutionary new “formation space” that provides early-stage entrepreneurs ... While AREA48 is open to anyone, ASU is ...
Breaking Medicine News(10 mins):Health News:Glaucoma drug can cause droopy eyelids 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4
... the United States Gulf Coast poses health risks to volunteers, ... a new commentary by UCSF researchers who spent time in ... health problems caused by the oil spill. The good ... factors, coastal air quality, is improving now that the oil ...
... dependent a man is on his female partner, the more ... to be presented at the 105th Annual Meeting of the ... to have the opposite effect: the more dependent they are ... engage in infidelity," said Christin Munsch, a sociology Ph.D. candidate ...
... 2010) Once thought to be a problem primarily in,the developed ... disability,in poorer countries. Almost two-thirds of the 7.6 million cancer ... A paper to be published online in the Lancet ... now discard the notion that cancer is,a ,disease of the ...
... congestion. Postnasal drip. Fatigue. These are hallmark ... nasal and sinus cavity. The illness strikes millions of Americans ... patients visit their primary care doctor. Treating sinusitis is difficult ... is viral or bacterial. Unfortunately little information on the ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... early trial, deep brain stimulation appeared to improve memory ... The authors caution that the findings are very preliminary ... from the study. However, test results and brain imaging ...
... Jenifer Goodwin HealthDay Reporter , FRIDAY, Aug. ... who regularly take acetaminophen, best known as Tylenol, were ... teens who never take the over-the-counter pain and fever ... linked to an increased chance of eczema and rhinoconjunctivitis, ...
Cached Medicine News:Health News:Health impact of Gulf Coast oil spill hazardous but improving 2Health News:Health impact of Gulf Coast oil spill hazardous but improving 3Health News:Men more likely to cheat if they are economically dependent on their female partners 2Health News:Global health leaders advocate for expanding cancer care in developing countries 2Health News:Global health leaders advocate for expanding cancer care in developing countries 3Health News:Primary care doctors get little information about chronic sinusitis 2Health News:Deep Brain Stimulation Studied for Alzheimer's 2Health News:Deep Brain Stimulation Studied for Alzheimer's 3Health News:Tylenol Use Linked to Asthma, Other Allergies in Teens 2Health News:Tylenol Use Linked to Asthma, Other Allergies in Teens 3Health News:Tylenol Use Linked to Asthma, Other Allergies in Teens 4
(Date:5/21/2013)... 21, 2013  The North Shore-LIJ Health System is ... hand-washing compliance at North Shore University Hospital in ... operating rooms at Forest Hills ... The new pilot program strengthens patient safety by ... (ORs), the first time in the US that remote ...
(Date:5/21/2013)... ALLENTOWN, Pa. , May 21, 2013  Lehigh ... additional TRU-D SmartUVC TM devices, adding to its ... With seven devices taking up residence within the network, ... in the U.S. to proactively combat superbugs and provide ... Short for Total Room Ultraviolet Disinfector, TRU-D – the ...
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 ... Inc. (NASDAQ: REGN) today announced that the New ... Phase 2a study results of dupilumab (SAR231893/REGN668) in patients ... antibody targeting the alpha subunit of the interleukin 4 ... and IL-13, drivers of Th2 (Type 2 helper T ...
Breaking Medicine Technology:North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 2North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 3North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 4Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7
... Health IT Services Group announced today that Acumen ... as a Complete EHR on December 30, 2010, by ... ONC-ATCB, in accordance with the applicable Eligible Provider certification ... Services. The 2011/2012 criteria support the Stage 1 meaningful ...
... PLEASANTON, Calif., Jan. 4, 2011 Thoratec Corporation (Nasdaq: ... mechanical circulatory support therapies to save, support and restore ... the 29th Annual J.P. Morgan  Healthcare Conference on Tuesday, ... chief executive officer, will provide an update on the ...
Cached Medicine Technology:Health IT Services Group's Acumen EHR, Version 6.0, Receives ONC-ATCB 2011/2012 Certification 2Health IT Services Group's Acumen EHR, Version 6.0, Receives ONC-ATCB 2011/2012 Certification 3
Blunt, fine curved shaft hook to unroll membranes. 24 gauge shaft with dark finish for reduced glare....
0.2 mm hook with curved shaft to reach over lens optic. Flat serrated handle with polished finish. Overall length: 4.8 inches. Most popular size or model....
Angled 45 degrees, 10 mm shaft with 0.2 mm tip. Round knurled handle with dull finish. Overall length: 4.6 inches....
Straight 31 mm shaft with flat handle and polished finish. 0.5 mm cup. Overall length: 5 inches....
Medicine Products: